Background: Morphine and other opioids are routinely used systemically and as wound infusions in the postoperative period. Their effect on wound and fracture healing remains unclear.
Objective: The primary outcome was to assess the potential cytotoxicity of clinically relevant concentrations of morphine on human fibroblasts.
Design: Laboratory in-vitro study.
Setting: Institute of Physiology, Zurich Center for Integrative Human Physiology, University of Zurich.
Materials: Monolayers of human fibroblasts.
Intervention(s): Exposure of human fibroblast monolayers to several concentrations of morphine, for different periods of time, with and without an artificially induced inflammatory process.
Main Outcome Measures: Cell count, cell viability, cell proliferation and apoptosis.
Results: A concentration, time and exposure-dependent cytotoxic effect of morphine-mediated apoptosis was observed. Simulated inflammatory conditions seemed to lessen toxic effects.
Conclusion: Cytotoxic effects of morphine are exposure, time and concentration dependent. Simulating aspects of inflammatory conditions seems to increase resistance to morphine cytotoxicity especially in the presence of higher concentration and longer exposure times.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/EJA.0000000000000509 | DOI Listing |
Curr Mol Med
January 2025
Department of Anesthesiology, Baoan Central Hospital of Shenzhen, Shenzhen, Guangdong Province, China.
Background: Morphine, a mu-opioid receptor (MOR) agonist commonly utilized in clinical settings alongside chemotherapy to manage chronic pain in cancer patients, has exhibited contradictory effects on cancer, displaying specificity toward certain cancer types and doses.
Objective: The aim of this study was to conduct a systematic assessment and comparison of the impacts of morphine on three distinct cancer models in a preclinical setting.
Methods: Viability and apoptosis assays were conducted on a panel of cancer cell lines following treatment with morphine, chemotherapy drugs alone, or their combination.
J Pharmacokinet Pharmacodyn
January 2025
Division of Systems Pharmacology and Pharmacy, Leiden Academic Center for Drug Research, Leiden University, Einsteinweg 55, Leiden, 2333 CC, The Netherlands.
P-glycoprotein (P-gp) is a key efflux transporter and may be involved in drug-drug interactions (DDIs) at the blood-brain barrier (BBB), which could lead to changes in central nervous system (CNS) drug exposure. Morphine is a P-gp substrate and therefore a potential victim drug for P-gp mediated DDIs. It is however unclear if P-gp inhibitors can induce clinically relevant changes in morphine CNS exposure.
View Article and Find Full Text PDFJ Anaesthesiol Clin Pharmacol
May 2024
Department of Anaesthesiology and Critical Care, Lady Hardinge Medical College, New Delhi, India.
J Anesth
January 2025
Division of Anesthesiology, Niigata University Graduate School of Medical and Dental Science, 1-757 Asahimachi-dori, Chuo-ku, Niigata, 951-8510, Japan.
Mol Clin Oncol
February 2025
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
We have been exploring biomarkers that could help physicians select the appropriate opioid for individualized treatment of cancer pain. Recently, we identified a single nucleotide polymorphism (SNP) of (rs17809012) as one such biomarker that was significantly associated with the analgesic effect of morphine. The current study measured the plasma concentrations of chemokines/cytokines in pre-treatment plasma samples of a total of 138 patients who were randomized to receive morphine (n=70) or oxycodone (n=68).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!